Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis/Human Genome Sciences Launch Second Phase III Albuferon Trial

This article was originally published in The Pink Sheet Daily

Executive Summary

Firms plan 2009 regulatory filings for the hepatitis C treatment.

You may also be interested in...



Human Genome Sciences Achieves Milestone For Albuferon Phase II Completion

HGS expects data from ACHIEVE pivotal program by spring 2009; global filings by fall 2009.

Human Genome Sciences Achieves Milestone For Albuferon Phase II Completion

HGS expects data from ACHIEVE pivotal program by spring 2009; global filings by fall 2009.

Vertex Hopes To PROVE Telaprevir’s Promise With Final Installment Of Phase II Program

Company plans to begin Phase III in the second half of 2007; further protocol discussions with FDA are planned for mid-2007.

Related Content

Topics

UsernamePublicRestriction

Register

PS078529

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel